{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:44:41Z","timestamp":1787856281927,"version":"build-2784847793"},"reference-count":80,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL159886-01"],"award-info":[{"award-number":["R01 HL159886-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL134776"],"award-info":[{"award-number":["R01 HL134776"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL139664"],"award-info":[{"award-number":["R01 HL139664"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.chest.2021.10.010","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T17:15:32Z","timestamp":1634145332000},"page":"1060-1072","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Novel Mechanisms Targeted by Drug Trials in Pulmonary Arterial Hypertension"],"prefix":"10.1016","volume":"161","author":[{"given":"David F.","family":"Condon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuti","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananya","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Auer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio","family":"Vazquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiral","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roham T.","family":"Zamanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicio A.","family":"de Jesus Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chest.2021.10.010_bib1","doi-asserted-by":"crossref","first-page":"F1000","DOI":"10.12688\/f1000research.18811.1","article-title":"The 6th World Symposium on Pulmonary Hypertension: what\u2019s old is new","volume":"8","author":"Condon","year":"2019","journal-title":"F1000Res"},{"issue":"1","key":"10.1016\/j.chest.2021.10.010_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s41030-019-00105-5","article-title":"Diagnosis and management of pulmonary hypertension in the modern era: insights from the 6th World Symposium","volume":"6","author":"Thomas","year":"2020","journal-title":"Pulm Ther"},{"issue":"2","key":"10.1016\/j.chest.2021.10.010_bib3","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1378\/chest.09-1140","article-title":"Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry","volume":"137","author":"Badesch","year":"2010","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2021.10.010_bib4","doi-asserted-by":"crossref","first-page":"1801887","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.chest.2021.10.010_bib5","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1093\/cvr\/cvaa350","article-title":"Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus","volume":"117","author":"Dunmore","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.chest.2021.10.010_bib6","doi-asserted-by":"crossref","first-page":"7265487","DOI":"10.1155\/2020\/7265487","article-title":"Novel molecular mechanisms of pulmonary hypertension: a search for biomarkers and novel drug targets-from bench to bed site","volume":"2020","author":"Gajecki","year":"2020","journal-title":"Oxid Med Cell Longev"},{"issue":"6","key":"10.1016\/j.chest.2021.10.010_bib7","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.14336\/AD.2020.0111","article-title":"Pathological mechanisms and potential therapeutic targets of pulmonary arterial hypertension: a review","volume":"11","author":"Xiao","year":"2020","journal-title":"Aging Dis"},{"issue":"4 Pt 1","key":"10.1016\/j.chest.2021.10.010_bib8","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1164\/ajrccm.162.4.2003124","article-title":"Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension: effect of prostacyclin therapy","volume":"162","author":"Eddahibi","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2021.10.010_bib9","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1183\/09031936.98.11030554","article-title":"Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients","volume":"11","author":"Humbert","year":"1998","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2021.10.010_bib10","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1172\/JCI35070","article-title":"Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents","volume":"119","author":"Izikki","year":"2009","journal-title":"J\u00a0Clin Invest"},{"issue":"13","key":"10.1016\/j.chest.2021.10.010_bib11","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMc051946","article-title":"Imatinib for the treatment of pulmonary arterial hypertension","volume":"353","author":"Ghofrani","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.chest.2021.10.010_bib12","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal of experimental pulmonary hypertension by PDGF inhibition","volume":"115","author":"Schermuly","year":"2005","journal-title":"J\u00a0Clin Invest"},{"issue":"11","key":"10.1016\/j.chest.2021.10.010_bib13","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.healun.2015.05.025","article-title":"Long-term safety and efficacy of imatinib in pulmonary arterial hypertension","volume":"34","author":"Frost","year":"2015","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.chest.2021.10.010_bib14","series-title":"Positioning imatinib for pulmonary arterial hypertension (PIPAH). NCT04416750. ClinicalTrials.gov","year":"2020"},{"key":"10.1016\/j.chest.2021.10.010_bib15","first-page":"1753","article-title":"Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment","volume":"8","author":"Pitsiou","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.chest.2021.10.010_bib16","series-title":"GB002 in adult subject with pulmonary arterial hypertension (PAH). NCT04456998. ClinicalTrials.gov","year":"2020"},{"issue":"1","key":"10.1016\/j.chest.2021.10.010_bib17","doi-asserted-by":"crossref","first-page":"1801899","DOI":"10.1183\/13993003.01899-2018","article-title":"Genetics and genomics of pulmonary arterial hypertension","volume":"53","author":"Morrell","year":"2019","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.chest.2021.10.010_bib18","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.3390\/ijms19092499","article-title":"Consequences of BMPR2 deficiency in the pulmonary vasculature and beyond: contributions to pulmonary arterial hypertension","volume":"19","author":"Andruska","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.chest.2021.10.010_bib19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijcard.2020.06.068","article-title":"The features of rare pathogenic BMPR2 variants in pulmonary arterial hypertension: comparison between patients and reference population","volume":"318","author":"Lyu","year":"2020","journal-title":"Int J Cardiol"},{"issue":"11","key":"10.1016\/j.chest.2021.10.010_bib20","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/ATVBAHA.119.313357","article-title":"Endothelial BMPR2 loss drives a proliferative response to BMP (bone morphogenetic protein) 9 via prolonged canonical signaling","volume":"40","author":"Theilmann","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.chest.2021.10.010_bib21","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/s41467-018-03672-4","article-title":"Identification of rare sequence variation underlying heritable pulmonary arterial hypertension","volume":"9","author":"Graf","year":"2018","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.chest.2021.10.010_bib22","doi-asserted-by":"crossref","first-page":"1801609","DOI":"10.1183\/13993003.01609-2018","article-title":"Germline BMP9 mutation causes idiopathic pulmonary arterial hypertension","volume":"53","author":"Wang","year":"2019","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.chest.2021.10.010_bib23","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1182\/blood-2006-07-034124","article-title":"Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells","volume":"109","author":"David","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.chest.2021.10.010_bib24","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1164\/rccm.201906-1141OC","article-title":"Characterization of GDF2 mutations and levels of BMP9 and BMP10 in pulmonary arterial hypertension","volume":"201","author":"Hodgson","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.chest.2021.10.010_bib25","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1161\/CIRCRESAHA.107.165530","article-title":"Bone morphogenetic protein-9 is a circulating vascular quiescence factor","volume":"102","author":"David","year":"2008","journal-title":"Circ Res"},{"issue":"Pt 6","key":"10.1016\/j.chest.2021.10.010_bib26","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1242\/jcs.002949","article-title":"BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis","volume":"120","author":"Scharpfenecker","year":"2007","journal-title":"J\u00a0Cell Sci"},{"issue":"7","key":"10.1016\/j.chest.2021.10.010_bib27","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nm.3877","article-title":"Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"issue":"543","key":"10.1016\/j.chest.2021.10.010_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5660","article-title":"ACTRIIA-Fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension","volume":"12","author":"Yung","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.chest.2021.10.010_bib29","series-title":"A\u00a0study of sotatercept for the treatment of pulmonary arterial hypertension (PAH) (PULSAR). NCT03496207. ClinicalTrials.gov","year":"2018"},{"key":"10.1016\/j.chest.2021.10.010_bib30","series-title":"A\u00a0study of sotatercept for the treatment of pulmonary arterial hypertension (SPECTRA). NCT03738150. ClinicalTrials.gov","year":"2018"},{"issue":"13","key":"10.1016\/j.chest.2021.10.010_bib31","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"156","key":"10.1016\/j.chest.2021.10.010_bib32","doi-asserted-by":"crossref","first-page":"200009","DOI":"10.1183\/16000617.0009-2020","article-title":"BNP\/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?","volume":"29","author":"Lewis","year":"2020","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.chest.2021.10.010_bib33","series-title":"A\u00a0study of sotatercept for the treatment of pulmonary arterial hypertension (STELLAR). NCT04576988. ClinicalTrials.gov","year":"2020"},{"issue":"1","key":"10.1016\/j.chest.2021.10.010_bib34","article-title":"Repurposing medications for treatment of pulmonary arterial hypertension: what\u2019s old is new again","volume":"8","author":"Prins","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.chest.2021.10.010_bib35","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1172\/JCI65592","article-title":"FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension","volume":"123","author":"Spiekerkoetter","year":"2013","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"10.1016\/j.chest.2021.10.010_bib36","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1164\/rccm.201411-2061LE","article-title":"Low-dose FK506 (tacrolimus) in end-stage pulmonary arterial hypertension","volume":"192","author":"Spiekerkoetter","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2021.10.010_bib37","doi-asserted-by":"crossref","first-page":"1602449","DOI":"10.1183\/13993003.02449-2016","article-title":"Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension","volume":"50","author":"Spiekerkoetter","year":"2017","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.chest.2021.10.010_bib38","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1164\/rccm.201509-1785OC","article-title":"Higher estradiol and lower dehydroepiandrosterone-sulfate levels are associated with pulmonary arterial hypertension in men","volume":"193","author":"Ventetuolo","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2021.10.010_bib39","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1183\/13993003.01083-2015","article-title":"Oestradiol metabolism and androgen receptor genotypes are associated with right ventricular function","volume":"47","author":"Ventetuolo","year":"2016","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2021.10.010_bib40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2042-6410-3-6","article-title":"BMPR2 expression is suppressed by signaling through the estrogen receptor","volume":"3","author":"Austin","year":"2012","journal-title":"Biol Sex Differ"},{"issue":"2","key":"10.1016\/j.chest.2021.10.010_bib41","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/cvr\/cvv106","article-title":"Oestrogen receptor alpha in pulmonary hypertension","volume":"106","author":"Wright","year":"2015","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.chest.2021.10.010_bib42","doi-asserted-by":"crossref","first-page":"L7","DOI":"10.1152\/ajplung.00337.2013","article-title":"Progress in solving the sex hormone paradox in pulmonary hypertension","volume":"307","author":"Lahm","year":"2014","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"1","key":"10.1016\/j.chest.2021.10.010_bib43","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ccm.2020.10.005","article-title":"Sex differences in pulmonary hypertension","volume":"42","author":"Morris","year":"2021","journal-title":"Clin Chest Med"},{"issue":"1","key":"10.1016\/j.chest.2021.10.010_bib44","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3390\/ijms21010116","article-title":"Estradiol metabolism: crossroads in pulmonary arterial hypertension","volume":"21","author":"Tofovic","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.chest.2021.10.010_bib45","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1164\/rccm.201403-0483OC","article-title":"Sex-dependent influence of endogenous estrogen in pulmonary hypertension","volume":"190","author":"Mair","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2021.10.010_bib46","doi-asserted-by":"crossref","first-page":"1602337","DOI":"10.1183\/13993003.02337-2016","article-title":"Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects","volume":"50","author":"Chen","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2021.10.010_bib47","series-title":"Pulmonary hypertension and anastrozole trial (PHANTOM). NCT03229499. ClinicalTrials.gov","year":"2017"},{"key":"10.1016\/j.chest.2021.10.010_bib48","series-title":"Tamoxifen therapy to treat pulmonary arterial hypertension (T2PAH). NCT03528902. ClinicalTrials.gov","year":"2018"},{"issue":"2","key":"10.1016\/j.chest.2021.10.010_bib49","first-page":"184","article-title":"Altered elastin and collagen synthesis associated with progressive pulmonary hypertension induced by monocrotaline: a biochemical and ultrastructural study","volume":"58","author":"Todorovich-Hunter","year":"1988","journal-title":"Lab Invest"},{"issue":"3","key":"10.1016\/j.chest.2021.10.010_bib50","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/(SICI)1097-4652(199603)166:3<495::AID-JCP4>3.0.CO;2-K","article-title":"Exogenous leukocyte and endogenous elastases can mediate mitogenic activity in pulmonary artery smooth muscle cells by release of extracellular-matrix bound basic fibroblast growth factor","volume":"166","author":"Thompson","year":"1996","journal-title":"J\u00a0Cell Physiol"},{"issue":"6","key":"10.1016\/j.chest.2021.10.010_bib51","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-3083.2009.02337.x","article-title":"Human gammadelta T\u00a0cells produce the protease inhibitor and antimicrobial peptide elafin","volume":"70","author":"Marischen","year":"2009","journal-title":"Scand J Immunol"},{"issue":"4","key":"10.1016\/j.chest.2021.10.010_bib52","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/hc0402.102866","article-title":"Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension","volume":"105","author":"Zaidi","year":"2002","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.chest.2021.10.010_bib53","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1164\/rccm.201412-2291OC","article-title":"Elafin reverses pulmonary hypertension via caveolin-1-dependent bone morphogenetic protein signaling","volume":"191","author":"Nickel","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2021.10.010_bib54","series-title":"Subcutaneous elafin in healthy subjects. NCT03522935. ClinicalTrials.gov","year":"2018"},{"issue":"3","key":"10.1016\/j.chest.2021.10.010_bib55","doi-asserted-by":"crossref","first-page":"2003957","DOI":"10.1183\/13993003.03957-2020","article-title":"Endothelial cells in the pathogenesis of pulmonary arterial hypertension","volume":"58","author":"Evans","year":"2021","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.chest.2021.10.010_bib56","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/2045-8932.109911","article-title":"Nitric oxide deficiency in pulmonary hypertension: pathobiology and implications for therapy","volume":"3","author":"Tonelli","year":"2013","journal-title":"Pulm Circ"},{"issue":"42","key":"10.1016\/j.chest.2021.10.010_bib57","doi-asserted-by":"crossref","first-page":"7168","DOI":"10.2174\/0929867327666200522215047","article-title":"The nitric oxide pathway in pulmonary arterial hypertension: pathomechanism, biomarkers and drug targets","volume":"27","author":"Lazar","year":"2020","journal-title":"Curr Med Chem"},{"issue":"5302","key":"10.1016\/j.chest.2021.10.010_bib58","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1126\/science.275.5302.964","article-title":"Isolation of putative progenitor endothelial cells for angiogenesis","volume":"275","author":"Asahara","year":"1997","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.chest.2021.10.010_bib59","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1183\/09031936.00112809","article-title":"Endothelial progenitors in pulmonary hypertension: new pathophysiology and therapeutic implications","volume":"35","author":"Fadini","year":"2010","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.chest.2021.10.010_bib60","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2353\/ajpath.2008.070705","article-title":"Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension","volume":"172","author":"Asosingh","year":"2008","journal-title":"Am J Pathol"},{"issue":"4","key":"10.1016\/j.chest.2021.10.010_bib61","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1161\/01.RES.0000157672.70560.7b","article-title":"Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease","volume":"96","author":"Zhao","year":"2005","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.chest.2021.10.010_bib62","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1165\/rcmb.2005-0115OC","article-title":"Microvascular regeneration in established pulmonary hypertension by angiogenic gene transfer","volume":"35","author":"Zhao","year":"2006","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.chest.2021.10.010_bib63","series-title":"Pulmonary hypertension: assessment of cell therapy (PHACeT). NCT00469027. ClinicalTrials.gov","year":"2007"},{"issue":"7","key":"10.1016\/j.chest.2021.10.010_bib64","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1161\/CIRCRESAHA.114.305951","article-title":"Endothelial NO-synthase gene-enhanced progenitor cell therapy for pulmonary arterial hypertension: the PHACeT trial","volume":"117","author":"Granton","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.chest.2021.10.010_bib65","series-title":"Study of angiogenic cell therapy for progressive pulmonary hypertension: intervention with repeat dosing of eNOS-enhanced EPCs (SAPPHIRE). NCT03001414. ClinicalTrials.gov","year":"2016"},{"issue":"3","key":"10.1016\/j.chest.2021.10.010_bib66","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1183\/13993003.01714-2015","article-title":"The emerging role of epigenetics in pulmonary hypertension","volume":"48","author":"Gamen","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2021.10.010_bib67","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijcard.2018.09.070","article-title":"Pathobiology, pathology and genetics of pulmonary hypertension: update from the Cologne Consensus Conference 2018","volume":"272S","author":"Olschewski","year":"2018","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.chest.2021.10.010_bib68","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/CIRCRESAHA.115.307004","article-title":"Bromodomain-containing protein 4: the epigenetic origin of pulmonary arterial hypertension","volume":"117","author":"Meloche","year":"2015","journal-title":"Circ Res"},{"issue":"7","key":"10.1016\/j.chest.2021.10.010_bib69","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrc3256","article-title":"BET domain co-regulators in obesity, inflammation and cancer","volume":"12","author":"Belkina","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"10.1016\/j.chest.2021.10.010_bib70","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1164\/rccm.201812-2275OC","article-title":"Multicenter preclinical validation of BET inhibition for the treatment of pulmonary arterial hypertension","volume":"200","author":"Van der Feen","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2021.10.010_bib71","series-title":"Apabetalone for pulmonary arterial hypertension: a pilot study (APPRoAcH-p). NCT03655704. ClinicalTrials.gov","year":"2018"},{"issue":"8","key":"10.1016\/j.chest.2021.10.010_bib72","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1242\/bio.20134853","article-title":"Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration","volume":"2","author":"Holmstrom","year":"2013","journal-title":"Biol Open"},{"issue":"2","key":"10.1016\/j.chest.2021.10.010_bib73","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.bbadis.2016.11.005","article-title":"Nrf2 signaling pathway: pivotal roles in inflammation","volume":"1863","author":"Ahmed","year":"2017","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.chest.2021.10.010_bib74","first-page":"A6896","article-title":"Results of interim analysis of the efficacy and safety of bardoxolone methyl in patients with pulmonary arterial hypertension associated with connective tissue disease (CTD) (the LARIAT study) [abstract]","volume":"195","author":"Oudiz","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2021.10.010_bib75","series-title":"Bardoxolone methyl evaluation in patients with pulmonary hypertension (PH)\u2014LARIAT. NCT02036970. ClinicalTrials.gov","year":"2014"},{"key":"10.1016\/j.chest.2021.10.010_bib76","series-title":"Bardoxolone methyl in patients with connective tissue disease-associated pulmonary arterial hypertension\u2014CATALYST. NCT02657356. ClinicalTrials.gov","year":"2016"},{"key":"10.1016\/j.chest.2021.10.010_bib77","series-title":"Extended access program to assess long-term safety of bardoxolone methyl in patients with pulmonary hypertension RANGER (RANGER). NCT03068130. ClinicalTrials.gov","year":"2017"},{"key":"10.1016\/j.chest.2021.10.010_bib78","doi-asserted-by":"crossref","first-page":"107423","DOI":"10.1016\/j.pharmthera.2019.107423","article-title":"Inhibition of serotonin synthesis: a novel therapeutic paradigm","volume":"205","author":"Bader","year":"2020","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.chest.2021.10.010_bib79","series-title":"A\u00a0study of rodatristat ethyl in patients with pulmonary arterial hypertension (ELEVATE 2). NCT04712669. ClinicalTrials.gov","year":"2021"},{"key":"10.1016\/j.chest.2021.10.010_bib80","first-page":"A3604","article-title":"A\u00a0pharmacokinetic\/pharmacodynamic based rationale for dose selection of the TPH inhibitor rodatristat ethyl in ELEVATE-2: a phase 2b study in pulmonary arterial hypertension [abstract]","volume":"2003","author":"Johnson","year":"2021","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369221040939?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369221040939?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:43:18Z","timestamp":1757925798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369221040939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0012369221040939"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2021.10.010","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Mechanisms Targeted by Drug Trials in Pulmonary Arterial Hypertension","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2021.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}